| Seizures, Focal
Afinitor vs Briviact
Side-by-side clinical, coverage, and cost comparison for seizures, focal.Deep comparison between: Afinitor vs Briviact with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBriviact has a higher rate of injection site reactions vs Afinitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Briviact but not Afinitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afinitor
Briviact
At A Glance
Oral
Daily
mTOR inhibitor
Oral; IV infusion
Twice daily
SV2A ligand
Indications
- Hormone receptor positive breast cancer
- Neuroendocrine tumor of pancreas
- Gastro-enteropancreatic neuroendocrine tumor
- Renal Cell Carcinoma
- Angiomyolipoma of kidney
- Subependymal Giant Cell Astrocytoma
- Seizures, Focal
- Seizures, Focal
Dosing
Hormone receptor positive breast cancer 10 mg orally once daily in combination with exemestane until disease progression or unacceptable toxicity.
Neuroendocrine tumor of pancreas, Gastro-enteropancreatic neuroendocrine tumor 10 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 10 mg orally once daily until disease progression or unacceptable toxicity.
Angiomyolipoma of kidney 10 mg orally once daily until disease progression or unacceptable toxicity.
Subependymal Giant Cell Astrocytoma Starting dose 4.5 mg/m2 orally once daily (AFINITOR or AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Seizures, Focal Starting dose 5 mg/m2 orally once daily (AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Seizures, Focal Adults (>=16 years): 50 mg twice daily (range 25-100 mg twice daily); pediatric patients >=50 kg: 25-50 mg twice daily (range 25-100 mg twice daily); pediatric patients <50 kg: weight-based dosing twice daily; IV injection at the same dose when oral administration is temporarily not feasible; dose adjustment required for all stages of hepatic impairment.
Contraindications
- Clinically significant hypersensitivity to everolimus or other rapamycin derivatives
- Hypersensitivity to brivaracetam or any inactive ingredient in BRIVIACT (bronchospasm and angioedema have occurred)
Adverse Reactions
Most common (>=30%) Stomatitis, infections, rash, fatigue, diarrhea, decreased appetite.
Serious Non-infectious pneumonitis, infections, severe hypersensitivity reactions, angioedema, stomatitis, renal failure, impaired wound healing, metabolic disorders (hyperglycemia, dyslipidemia), myelosuppression, radiation sensitization and recall.
Postmarketing Thrombotic microangiopathy, cardiac failure (including with pulmonary hypertension), acute pancreatitis, cholecystitis, cholelithiasis, sepsis, reflex sympathetic dystrophy, arterial thrombotic events, lymphedema, radiation sensitization and recall.
Most common (>=5%) Somnolence and sedation, dizziness, fatigue, nausea and vomiting symptoms
Serious Suicidal behavior and ideation, neurological adverse reactions, psychiatric adverse reactions, hypersensitivity (bronchospasm and angioedema), serious dermatologic reactions, hematologic abnormalities (decreased white blood cell and neutrophil counts)
Postmarketing Serious dermatologic reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis)
Pharmacology
Everolimus is an mTOR inhibitor that binds the intracellular protein FKBP-12 to form an inhibitory complex with mTORC1, suppressing downstream effectors (S6K1, 4E-BP1) involved in protein synthesis, cell proliferation, and angiogenesis, and reducing HIF-1 and VEGF expression; mTOR pathway dysregulation occurs in several human cancers and in tuberous sclerosis complex.
Brivaracetam is an anticonvulsant with high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain; the precise mechanism by which it exerts anticonvulsant activity is not fully established.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afinitor
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Briviact
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (3/12) · Qty limit (0/12)
UnitedHealthcare
Afinitor
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Briviact
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (3/8) · Qty limit (0/8)
Humana
Afinitor
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Briviact
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Afinitor.
$10/momo
Briviact Patient Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfinitorView full Afinitor profile
BriviactView full Briviact profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.